One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.
The no-adjustment finding is limited to the named renal range; severe renal disease and renal dialysis are excluded.
What to reconcile: Confirm CrCl, dialysis status, contraindications and CYP3A4 co-medications before applying the renal statement.
Open this note and its source referencesConfirm CrCl, dialysis status, contraindications and CYP3A4 co-medications before applying the renal statement.
Dialysis evidence: Use is not recommended / excluded in the named dialysis population; not a dialysis dose
Nitrates and guanylate-cyclase stimulators are contraindicated. Do not use with strong CYP3A4 inhibitors; moderate CYP3A4 inhibitors limit the dose to 50 mg in 24 hours.
A renal no-adjustment statement is not an assessment of cardiovascular suitability or other contraindications. No dialysis regimen is supplied.
| Renal setting | Source-specific action and limits |
|---|---|
| CrCl >=30 to <90 mL/min | No renal dose adjustment. Other dosing restrictions and interactions still apply. |
| Severe renal disease or renal dialysis | Do not use; pharmacokinetics have not been studied in these populations. |
| Renal setting | Source-specific action and limits |
|---|---|
| CrCl >=30 to <90 mL/min | No renal dose adjustment. Other dosing restrictions and interactions still apply. |
| Severe renal disease or renal dialysis | Do not use; pharmacokinetics have not been studied in these populations. |
Nitrates and guanylate-cyclase stimulators are contraindicated. Do not use with strong CYP3A4 inhibitors; moderate CYP3A4 inhibitors limit the dose to 50 mg in 24 hours.
A renal no-adjustment statement is not an assessment of cardiovascular suitability or other contraindications. No dialysis regimen is supplied.
RDM68-avanafil-stendra-cb2390b54b · Source locator: Sections 8.6, 4.1, 4.3 and 2.3
The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=avanafil-stendra&s1=RDM68-avanafil-stendra-official&h1=25e26930a1a91257cd4052c008624718a3e469c8b0a64b69081ff028bf8abca8